In this episode of The Swine Health Blackbelt Podcast, Dr. Troy Kaiser from Boehringer Ingelheim shares the latest on PCV2 immunization innovation and how shifting genotypes influence swine health protocols. He details safety and efficacy trials, label claims, and what this means for herd-level protection. Learn what’s next in immunization strategy and how to optimize immunity. Listen now on all major platforms!"Even without overt clinical signs, PCV2 can still impact growth, performance, efficiency, and herd consistency."𝗠𝗲𝗲𝘁 𝘁𝗵𝗲 𝗴𝘂𝗲𝘀𝘁: Dr. Troy Kaiser is a Principal Scientist and Clinical Project Lead & Laboratory Study Lead for livestock immunizers at Boehringer Ingelheim Animal Health, leading clinical studies for swine immunizer development. He earned his B.S. and M.S. from South Dakota State University, followed by his DVM. from Iowa State University. With decades of experience in swine virology, his work focuses on advancing the efficacy and safety of immunizers for PCV2.Liked this one? Don’t stop now — Here’s what we think you’ll love!Dr. Pablo Piñeyro: PCV4 & Co-infections | Ep. 139Dr. Tyler Bauman: PRRS Control in Grow-Finish Pigs | Ep. 156What you will learn:(00:00) Highlight(00:54) Introduction(03:49) PCV2 trends(05:14) Efficacy testing(06:06) Message for producers(09:51) Protection strategy(11:24) Safety profile standards(15:17) Closing thoughtsThe Swine Health Blackbelt Podcast is trusted and supported by innovative companies like:* Boehringer Ingelheim- Elanco𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.Website: The Swine Health Blackbelt PodcastInstagram: Swine CampusLinkedIn: Swine Campus

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related